|Videos|February 20, 2023
Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab
Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
The top 5 OncLive TV videos of the week.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5